Otsuka and Medimetriks Sign Licensing Agreement for Development and Commercialization of OPA-15406 in the U.S. for Atopic Dermatitis

Otsuka Pharmaceutical Co., Ltd. and Medimetriks Pharmaceuticals, Inc. (based in Fairfield, New Jersey, U.S.) announced that they entered into a licensing agreement on February 8 (U.S. date).
The agreement provides Medimetriks, a company specializing in the dermatology market, with development, marketing and manufacturing rights to OPA-15406 in the United State. Otsuka receives a USD 22 million lump sum payment (approximately Yen 2.5 billion) and additional milestones through regulatory approval.
Otsuka discovered the molecule OPA-15406, a new therapeutic agent in development for atopic dermatitis. OPA-15046 has inhibitory effects on phosphodiesterase IV (PDE-4).

Suggested Articles

The Shire bid Takeda’s been discussing is getting real. The Japanese drugmakers is gauging lender interest in financing the buy.

After initial doubts, some analysts now like Takeda's chances of pulling off a deal for embattled Shire.

Sanofi is out another potential buyer for its European generics business as India-based Torrent Pharma exited deal talks, according to a report.